The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
Open accessAbstract
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase (CYP17), the key enzyme which catalyzes the biosynthesis of androgens from progestins, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Galeterone or TOK-001, formerly called VN/124-1) was identified as a selective development candidate which modulates multiple targets in the androgen receptor (AR) signaling pathway. This drug annotation summarizes the mechanisms of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for galeterone, which has successfully completed phase II clinical development in men with castration resistant (advanced) prostate cancer (CRPC). Phase III clinical studies in CRPC patients are scheduled to begin in early 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Pereira de Jésus‐Tran, K., Côté, P., Cantin, L., Blanchet, J., Labrie, F., & Breton, R. (2006) · Protein Science · doi:10.1110/ps.051905906 · Cited by 278
Cited by
Xu, Z., Zhao, S.-J., & Liu, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111700 · Cited by 520
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Formation and Cleavage of C–C Bonds by Enzymatic Oxidation–Reduction Reactions
Guengerich, F. P., & Yoshimoto, F. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00031 · Cited by 296
Metadata
- Authors
- Njar, V. C. O., & Brodie, A. M. H.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-01-28
- Volume
- 58
- Issue
- 5
- Pages
- 2077-2087
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2058786468
- Cited by
- 200
- References
- 2
- FWCI
- 21.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer. https://app.cochat.ai/papers/10.1021/jm501239f
- The paper
- Njar, V. C. O., & Brodie, A. M. H. (2015). Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm501239f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.